10-K: Third Harmonic Bio Submits 10-K Filing, Outlines Progress on Oral KIT Inhibitor Program

Third Harmonic Bio's 10-K filing details the company's focus on developing oral KIT inhibitors for inflammatory diseases, including the planned initiation of clinical studies for THB335 in Q2 2024.

Summary

• Third Harmonic Bio is a biopharmaceutical company focused on developing oral KIT inhibitors for inflammatory diseases.
• The company's lead candidate, THB335, is a next-generation oral small molecule inhibitor of KIT, designed to mitigate hepatotoxicity risks observed with their first-generation candidate, THB001.
• An Investigational New Drug (IND) application for THB335 has been submitted to the FDA, with clinical studies planned to begin in the second quarter of 2024.
• Phase 2 development of THB335 is expected to initially focus on chronic spontaneous urticaria.
• The company discontinued its Phase 1b trial of THB001 due to liver transaminitis in two patients, but mechanistic studies identified a reactive metabolite as the likely cause, which THB335 is designed to address.
• Third Harmonic Bio had $269.1 million in cash and cash equivalents as of December 31, 2023, which they believe will fund operations through at least 2026.
• The company reported net losses of $35.2 million and $30.8 million for the years ended December 31, 2022 and 2023, respectively, and expects to continue to incur losses for the foreseeable future.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made progress in developing THB335 and has a strong cash position, it also faces significant risks and challenges, including a history of losses, a material weakness in internal controls, and the need for additional funding. The discontinuation of the THB001 trial and the inherent risks of drug development temper the positive aspects.

Positives

• THB335 retains the potency and selectivity of THB001, with structural modifications to mitigate hepatotoxicity risk.
• Nonclinical studies of THB335 have demonstrated the ability to deplete mast cells across different tissue types.
• The company believes its current cash and cash equivalents will fund operations through at least 2026.
• The company has a strong management team with experience in drug discovery, development, and commercialization.

Negatives

• The company has a limited operating history and has not completed any clinical trials beyond Phase 1.
• The company has a history of significant net losses and expects to continue to incur losses for the foreseeable future.
• The company identified a material weakness in its internal control over financial reporting.
• The company discontinued its Phase 1b trial of THB001 due to liver transaminitis in two patients.

Risks

• The company will need substantial additional funds to pursue its business objectives, which may not be available on acceptable terms.
• Drug development is a lengthy and expensive process, and the outcome of clinical testing is inherently uncertain.
• Future clinical trials may reveal significant adverse events not seen in nonclinical studies.
• The company faces competition from entities that have made substantial investments into the rapid development of novel treatments for allergic and inflammatory diseases.
• The company relies on third parties to conduct clinical trials and perform research and nonclinical studies.
• The regulatory approval process is highly uncertain, and the company may be unable to obtain U.S. or foreign regulatory approval.
• Even if the company is able to commercialize THB335 or any of its oral future KIT inhibitor product candidates, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies.

Future Outlook

The company plans to initiate clinical studies for THB335 in Q2 2024, with Phase 2 development initially focused on chronic spontaneous urticaria. They expect to continue to incur losses for the foreseeable future as they advance their research and development programs.

Management Comments

• The company is focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases.
• The company believes that KIT inhibition may find wide therapeutic utility across a range of inflammatory indications.
• The company's goal is to be a leader in the oral KIT inhibitor space.

Industry Context

The company is operating in a competitive landscape with numerous companies developing treatments for allergic and inflammatory conditions. The company is focusing on oral small molecule inhibitors of KIT, which they believe offers advantages over other approaches such as injectable biologics.

Comparison to Industry Standards

• The company's approach of targeting KIT with a small molecule inhibitor is similar to Celldex's CDX-0159, a monoclonal antibody KIT inhibitor, but differs in modality and administration.
• The company's focus on oral administration is a key differentiator from injectable biologics like Xolair, which is used to treat chronic spontaneous urticaria.
• The company's development of THB335, designed to mitigate hepatotoxicity risks, addresses a key challenge observed with other KIT inhibitors like imatinib.
• The company's reported net losses are typical for a clinical-stage biopharmaceutical company, but the company's cash position is relatively strong compared to other companies at a similar stage.

Related Party Transactions

• The company has a license agreement with Novartis, a significant beneficial owner.
• The company leased office space from Atlas Venture, a significant beneficial owner, through September 2022.
• The company forgave a promissory note from its CEO in 2022 and paid a one-time special bonus to offset the tax liability.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises and potential losses due to the company's ongoing operating losses.
• Employees may benefit from the company's growth and development, but also face the risk of job insecurity due to the company's financial situation.
• Patients with inflammatory diseases may benefit from the development of new treatments, but the success of THB335 is not guaranteed.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company plans to initiate clinical studies for THB335 in Q2 2024.
• Phase 2 development of THB335 is expected to initially focus on chronic spontaneous urticaria.
• The company will continue to explore development opportunities across a range of other indications where an oral KIT inhibitor may provide benefit.

Key Dates

Keywords

KIT inhibitor, THB335, inflammatory diseases, mast cells, chronic urticaria, biopharmaceutical, clinical trials, drug development, hepatotoxicity, oral small molecule